Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Breast Neoplasms, Male

• ETHAN - ET for Male BC
• Testosterone & Tamoxifen Trial
• A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy
• HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
• Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
• Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer
• Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
• CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)
• Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
• Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
• Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
• Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
• A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases
• Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
• FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
• Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
• Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer
• 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
• Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
• Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
• Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
• Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
• Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
• Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
• Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
• Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
• Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
• Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
• Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
• Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
• Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
• Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
• Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
• Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
• RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
• RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
• Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
• Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
• Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer
• RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
• Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
• Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
• Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer
• Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
• Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
• Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
• Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
• Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
• Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
• Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
• Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
• Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
• Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
• Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
• Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
• Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery
• Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
• Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer
• Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer
• AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
• Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
• Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
• Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer
• A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
• Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer
• Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
• Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
• Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
• Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
• FR901228 in Treating Patients With Metastatic Breast Cancer
• Sorafenib in Treating Patients With Metastatic Breast Cancer
• 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
• Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
• Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
• GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer
• Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
• Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer
• Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
• Decitabine in Treating Patients With Advanced Solid Tumors
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
• Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
• Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer
• Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer
• Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer
• Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer